This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Meruvax II

Merck & Co., Inc.

Drug Names(s): Rubella Virus Vaccine Live

Description: Meruvax II is a live virus vaccine for vaccination against rubella (German measles). It is a sterile lyophilized preparation of the Wistar Institute RA 27/3 stratin of live attentuated rubella virus.

The Advisory Committee on Immunization Practices (ACIP) recommends that a combination measles, mumps, rubella vaccine (MMR) be used in place of single antigen vaccines such as Meruvax in all its applications.

Meruvax II News

Pink Sheet R&D In Brief

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug